{"name":"Q32 Bio Inc.","slug":"q32-bio-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ADX-914","genericName":"ADX-914","slug":"adx-914","indication":"Relapsed or refractory multiple myeloma","status":"phase_2"}]}],"pipeline":[{"name":"ADX-914","genericName":"ADX-914","slug":"adx-914","phase":"phase_2","mechanism":"ADX-914 is a monoclonal antibody targeting CD47.","indications":["Relapsed or refractory multiple myeloma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxPVXVVZGRhZkhFVGdIZi1OU3VOMmRKcGJsUmRIQm9SQ2I4LWU0MXprdXpPRFJacUlQR290bG1uSGFBSXFHcUhNU3pHbnRKS0RNQlZmQlMyZ0U1Vmdjb0FXVjlDN0lzWk55RS1XbDdLNVRHZFFMckxqa25jazJiLVkwQXlYRXY4b2J1OFZ5NnNuS1NMSTJlS1JCOTJMd2dRSVYtbUdRdElnbGlyS0dDbjFtUW9WaGJ0UnRmOU5DR3U0aV8zcUo1WTY5Slg2MTNTSWF5UnV2WkVXVlJiQWlQLU5uV2Zxelo?oc=5","date":"2026-03-12","type":"earnings","source":"Markets Mojo","summary":"Q32 Bio, Inc. Experiences Comprehensive Evaluation Adjustment Amid Financial Landscape Changes - Markets Mojo","headline":"Q32 Bio, Inc. Experiences Comprehensive Evaluation Adjustment Amid Financial Landscape Changes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxNeFhfVklmTzl0Nm5rMXZ3OTJvdWtQVjU5MURldklJeER4NlViSjNFWThVV3BoaTFPQndaYlRnSTU2OEtsX3dLTnAyTlBlLTBiTlR3eEFnV3lQMmFqYXktekdSZHVUM1drejNKdWxMVjB4bENEWjRaLS1wbXFfeXZ3X2RQVGpyazJEY0JRNU5WbEQ5T1RQczgyRDFTcXhYQVFVQ3EzV0E1cFhobXFRTzNWTTBVeldBZndaRTJjRllmdFpGZkRpZnF3emJGaTRrMjZSb2FXZEp3?oc=5","date":"2026-03-10","type":"earnings","source":"PR Newswire","summary":"Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire","headline":"Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPLWk1ZkgwV25ZOUh3cmx0ZjZJY2prOGFKcXZRTG1od2ZNSVFDS2NqcWxVbUcwOWRNZkFTTldqTVBZYTRHR0lQakxwVnRLNXJyd3kyN0VfRzN0QjZzLVFwTllubjg4S2VIclpRbnN4UDY0VUJLMGt5WTN0dmlVc29zdVE5aERDSWRVb2g0aDYwLVp5OUF0MkRjM3NWRDNpakstUW5CUWV6bVpzUUNIbGp4YlhTSQ?oc=5","date":"2026-02-17","type":"earnings","source":"PR Newswire","summary":"Q32 Bio Announces $10.5 Million Registered Direct Offering - PR Newswire","headline":"Q32 Bio Announces $10.5 Million Registered Direct Offering","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNNF8yRVVRdmFIVnN4aUFZOXpLSzhrUU1nZE1Wd241MllMMldSMVROMmduVHJKa1lEZS1kMFQ3MTIzcXhBTVVOR1RCSGZWRk1ZMXFraTRZTmNYODc1dEY4VGdUelUxM0pnWWVwd09LaHpOd0xOUGd3OWZ4eV9JODNWYnVUd1ZkMkZleGd3?oc=5","date":"2025-12-31","type":"pipeline","source":"The Business Journals","summary":"More than 4,600 Massachusetts biotech workers lost jobs in 2025 as industry contracts - The Business Journals","headline":"More than 4,600 Massachusetts biotech workers lost jobs in 2025 as industry contracts","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-07","type":"earnings","source":"simplywall.st","summary":"Q32 Bio Insiders Benefit From Selling Stock At US$2.86 - simplywall.st","headline":"Q32 Bio Insiders Benefit From Selling Stock At US$2.86","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQRFd0Y2E2NlNBT1F5X044ZzkwRFo5RDlITGtVdWdrWFRfUlpqdVQzTGI1dWV2UGtOQVAzTEtRWXpRTTJLNzh1Y2NfM1FUdmNfMG9BWS1INExEYVJ4amFLb1h6R3VtWWh0dXN1ajlRMFloUEYtYWU5bHR5d09JTm95RUZQNzBkeTVuWTBCUUoxUDEyc05DVTB5Wlh1ZjcxTFF2czJRV3FR?oc=5","date":"2025-12-01","type":"earnings","source":"The Pharma Letter","summary":"Q32 Bio skyrockets as it sells complement inhibitor ADX-097 - The Pharma Letter","headline":"Q32 Bio skyrockets as it sells complement inhibitor ADX-097","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNZzNucVd5NmJEZ1hjSUVGZ1p6U3hGQi1tYjBwSXJMTzZLMVFkZ1Bsb1plS1JSSFRFSDgxcjJBQkZTWDRZSFRWTEpiYk81RVhWN0Rsc2NISHJ2bmk5NE03dkxEeWl1MVMtN3hnVTU3Zy1sQjBkb1JrclUzQU9JcF94VUVCRnRKU1dfWjBfTlpES2NZRldNNjNZU2RuSzBzUFdaVlhMaEJuOHJBSEoyMkpJM2RyZDMteEtja2NuLXBwQ28?oc=5","date":"2025-12-01","type":"earnings","source":"TechStock²","summary":"Q32 Bio (QTTB) Stock Explodes After $592 Million Akebia Deal – Latest News, Analyst Targets and 2027 Outlook - TechStock²","headline":"Q32 Bio (QTTB) Stock Explodes After $592 Million Akebia Deal – Latest News, Analyst Targets and 2027 Outlook - TechStock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPckxDakNINW1IMDVxRXd3WTZXZ2VFbW9MMUh0c2xCWVBFQmhCOF9nNnNJZXJBV0ZTb3ZTQWwzY2RiRjRvd0lZVzM5ZXpUZ0xtTFdYak1CVzA1dW1yREljZzllSkNLZ2JoMlhmcEllcXA0bTRzak0xRXdtX3BkSFhGcUd3dE5IdUdHekJaN0dyVTZVMTdaSk9BYjhWNTRkeUE?oc=5","date":"2025-12-01","type":"earnings","source":"PR Newswire","summary":"Q32 Bio Sells Complement Inhibitor ADX-097 - PR Newswire","headline":"Q32 Bio Sells Complement Inhibitor ADX-097","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE83eEVrdVB4VTNUNE9DX2VMLW1EX3padzNMRElyZ082X2U0T1VNZDZvMjFFcGo1VkhwZ25UWXJ1YkRfQ3ItQjVadURlMlFTUXZuQVdrRVQ5SHdieTBja0hHalN4clI5LWZs?oc=5","date":"2025-10-21","type":"regulatory","source":"MarketBeat","summary":"Q32 Bio (QTTB) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat","headline":"Q32 Bio (QTTB) FDA Approvals, PDUFA Dates & Drug Alerts 2026","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxQdnZ4UEJpaTMwazZtbm93QjFYOHFmNWVsM3BCYkliNDA2T2dHSElCZW5CczFuVklUQWVXOHVoMkdIMFNfNklYRHF3bUh1ZWx4ZDhZUUNMeXNvek5aWnM3Zks3WGNMOVFsSVRhbnhlYnotWHBQRHlSMmlfeVY0Q0FBTzJLZ3ZCMmU2bjE1X0IxM1dzMkEwa0tYVjFLUE1GNWZnUGFnektBbW14c0pYWnc?oc=5","date":"2025-02-11","type":"trial","source":"Clinical Trials Arena","summary":"Q32 Bio halts trials amid job cuts and pivots to alopecia treatment - Clinical Trials Arena","headline":"Q32 Bio halts trials amid job cuts and pivots to alopecia treatment","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQd2JPQlBJQmRMN29XY3dCQnJhRU0xVU5BMFV1QS1rSmhxQUl5cUZBanVmczZER3VaUElHZWhYeGhDdmJwS3hOUTlEcEk5dEhwUjNYem1xWlZIbjdzYjZ0U1Znbm1nNml0SmVqdFZwM2d5Wk1VajloaFJhQU1QTXl4S0tfTV8zZXNRdlZPdWtOVmRmVDk5RzhnUFJXVWE?oc=5","date":"2024-12-11","type":"trial","source":"BioPharma Dive","summary":"Q32 Bio battered by study failure of immune drug - BioPharma Dive","headline":"Q32 Bio battered by study failure of immune drug","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPUTQzbFNWOUdZZHh0bEhFZF9KSEk5YmRuZ2JUUjc0T1QwVzk2SmtxNlQ1N08zR0pCUlZOaVhqcEtJRGlKVDdXdmNubThoZjA3YUVjWDl6M1RCU25tZlliRkVWdUVEYWFhV2NyenRWRng2SDUzUkpIUlp5ZVhBTUdNVk9UZFZiNWRBVV94b28xR3ZCNzg1VDlEenhNOFZKbmpWd2ZEZ3A3TmxWdkt4UTZEdm1kd0RfY2kzNnA0RzNmbnJjTTTSAdMBQVVfeXFMT3lqX0hMNHlSdk9vTk14S0xma2V5elE0RVE2MUVwNDJNY2hQWTI0ZlFSTkFVek5fTEQxcVgxQjY3N0pvSkdnNHdHUTRfaFpwSzdLNW5Zb3FMV2d3SjFOeFhfQlpxc0w1S0xWOXVnSW9tOURFSFVEVlBSQVlRSjNzNk93ZlQtcTEzOUgtaGRzdzNEOWg1a1IwTVZ5YWVBb3RXQUtMMUpNNzl2QVJBZmtwUDFsM250Ykc0ZG5aODF2UVpYeWJzb0FnMVp3XzdqZHlldFFFZw?oc=5","date":"2024-08-02","type":"earnings","source":"University of Colorado Anschutz","summary":"Could Q32 Bio’s ‘Skeleton Key’ Open the Door to New Treatments for an Array of Diseases? - University of Colorado Anschutz","headline":"Could Q32 Bio’s ‘Skeleton Key’ Open the Door to New Treatments for an Array of Diseases?","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}